Dr. Christopher Overgaard is an interventional cardiologist and a clinician-investigator at the Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network (UHN).
He is the Clinical Director of the Coronary Intensive Care Unit at Toronto General Hospital and the Medical Director the Cardiac Catheterization Laboratories across UHN.
He is an active clinician and clinical researcher with teaching and administrative duties.
His clinical focus has been on complex coronary disease in the setting of myocardial infarction and cariogenic shock. He also has a clinical interest in patients with kidney disease and coronary artery disease.
Dr. Overgaard is actively involved in many research endeavours in the realm of cardiac intensive care, myocardial protection research and clinical outcomes research.
Industry Expertise (2)
Areas of Expertise (4)
University of Toronto: M.D., Medicine 1999
Queen's University: Master's degree, Respiratory Physiology 1995
Media Appearances (5)
‘TandemHeart’ helps make high-risk heart patients strong enough for surgery
“The TandemHeart device is a very powerful motor that helps support the heart through very complex procedures,” said Dr. Chris Overgaard, an interventional cardiologist at the Peter Munk Cardiac Centre...
Toronto doctors complete first-in-Canada heart procedure without surgery
Cardiologist Dr Christopher Overgaard said Barton's heart was too weak for open-heart surgery. So, the doctor asked if he'd be interested in trying something new.
The TandemHeart takes over for a weak heart when doctors are working on it like fixing a car engine while it’s running, Overgaard said.
“It acts as an artificial pump, sucking the blood out of the body – energising it, then pumping it back in,” said Alan Daly, the Canadian manager for TandemHeart.
"That allowed the rest of the body to get all the perfusion it needed while we're working away on the chamber that is supposed to do that," Overgaard said, CBCnews reported...
'I'm able to live life again': Toronto doctors complete first-in-Canada heart procedure
Cardiologist Dr. Christopher Overgaard said Barton's heart was too weak for open-heart surgery. So, the doctor asked if he'd be interested in trying something new...
New device helps doctors perform on weak hearts
How can doctors be better at communicating? Let patients' families join them on rounds
The Globe and Mail
Dr. Christopher B. Overgaard is an interventional cardiologist at the Peter Munk Cardiac Centre in Toronto. He is also the Medical Director of the Coronary Intensive Care Unit (CICU), and Associate Director, Research and Innovation in Interventional Cardiology and Coronary Intensive Care at the University Health Network (UHN).
Myocardial contrast echocardiography during angiography is critical in identifying appropriate septal perforator(s) for alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy. We evaluated whether there were other angiographic and/or echocardiographic markers that might identify patients who are anatomically suitable for ASA.
A man presented with hypothyroidism, dilated cardiomyopathy, a pericardial effusion, liver failure, and polycythaemia. He had a history of bilateral hip replacements and new-onset hip pain. The patient progressed to develop shock. Given his acutely profound ...
The purpose of this study was to investigate whether a relationship exists between an acute reduction in resting left ventricular outflow tract (LVOT) gradient with balloon occlusion and the final invasive gradient response following alcohol septal ablation (ASA).
An observational study determining the long-term impact of chronic kidney disease (CKD) on patients undergoing percutaneous coronary intervention at a tertiary cardiac referral center. CKD is associated with poor in-hospital outcomes after percutaneous coronary intervention, but its effect beyond 1 year, particularly in the drug-eluting stent (DES) era, has not been reported.
Inotropic and vasopressor agents have increasingly become a therapeutic cornerstone for the management of several important cardiovascular syndromes. In broad terms, these substances have excitatory and inhibitory actions on the heart and vascular smooth muscle, as well as important metabolic, central nervous system, and presynaptic autonomic nervous system effects...